Table 1.
Baseline and treatment characteristics of patients with malignant pleural mesothelioma in Group A (BAP1 inactivating mutation/copy number loss, n-8) and Group B (without a BAP1 alteration/not tested, n-37).
| Group A (n-8) | Group B (n-37) | Group B1 (n-6) | Group B2 (n-31) | p value (between A and B) | p value (between A and B1) | |
|---|---|---|---|---|---|---|
|
Age at diagnosis, years
(median, range) |
65 (25-76) | 69 (30-93) | 77 (71-90) | 66 (30-93) | 0.2 | 0.02 |
| Sex, n (%) | 0.7 | 0.6 | ||||
| Female | 3 (37) | 11(30) | 1 (17) | 10 (32) | ||
| Male | 5 (63) | 26 (70) | 5 (83) | 21 (68) | ||
| Asbestos exposure, n (%) | 0.4 | 1.0 | ||||
| Yes | 2 (25) | 15 (41) | 2 (33) | 13 (42) | ||
| No | 5 (63) | 15 (41) | 4 (67) | 11 (35) | ||
| NA | 1 (12) | 7(18) | 0 (0) | 7 (23) | ||
| Family history of malignancy, n (%) | 2 (25) | 4 (11) | 1 (17) | 3 (10) | 1.0 | 1.0 |
| Histology, n (%) | 0.6 | 1.0 | ||||
| Epithelioid | 7 (88) | 31 (85) | 6 (100) | 25 (82) | ||
| Sarcomatoid | 0 (0) | 2 (5) | 0 (0) | 2 (6) | ||
| Biphasic | 1 (12) | 2 (5) | 0 (0) | 2 (6) | ||
| NA | 0 (0) | 2 (5) | 0 (0) | 2 (6) | ||
| PD-L1 TPS, n (%) | 0.03 | 0.08 | ||||
| >50% | 2 (25) | 0 (0) | 0 (0) | 0 (0) | ||
| 1-50% | 0 (0) | 5 (14) | 3 (50) | 2 (6) | ||
| <1% | 1 (12) | 2 (5) | 1 (17) | 1 (3) | ||
| NA | 5 (63) | 30 (81) | 2 (33) | 28 (91) | ||
| MSI high/MMR deficient, n (%) | 0 (0)* | 0 (0)** | 0 (0) | 0 (0) | 0.4 | 0.6 |
| TMB, mut/Mb, (median, range) | 3 (0.8-5)¥ | 1.5 (0-2)¥¥ | 1.5 (0-2)¥¥ | NA | 0.2 | 0.2 |
|
Stage at diagnosis (AJCC Cancer
Staging, 8th edition), n (%) |
0.5 | 0.5 | ||||
| I/II | 1 (12) | 9 (24) | 2 (33) | 7 (22.5) | ||
| III | 3 (38) | 19 (51) | 3 (50) | 16 (52) | ||
| IV | 3 (38) | 8 (22) | 1 (17) | 7 (22.5) | ||
| NA | 1 (12) | 1 (3) | 0 (0) | 1 (3) | ||
| ECOG PS at diagnosis, n (%) | 1.0 | 1.0 | ||||
| 0/1 | 7 (88) | 30 (81) | 6 (100) | 24 (78) | ||
| 2/3/4 | 1 (12) | 5 (14) | 0 (0) | 5 (16) | ||
| NA | 0 (0) | 2 (5) | 0 (0) | 2 (6) | ||
| EORTC prognostic scoring system | 0.6 | 1.0 | ||||
| Good-prognosis | 5 (63) | 22 (59) | 5 (83) | 17 (55) | ||
| Poor-prognosis | 1 (12) | 11 (30) | 0 (0) | 11 (35) | ||
| NA | 2 (25) | 4 (11) | 1 (17) | 3 (10) | ||
| CALGB prognostic scoring system | 0.7 | 0.5 | ||||
| 1/2 | 2 (25) | 12 (32) | 3 (50) | 9 (29) | ||
| 3/4 | 2 (25) | 18 (49) | 2 (33) | 16 (51) | ||
| 5/6 | 1 (12) | 3 (8) | 0 (0) | 3 (10) | ||
| NA | 3 (38) | 4 (11) | 1 (17) | 3 (10) | ||
| Surgery, n (%) | 1.0 | 1.0 | ||||
| EPP | 1 (12) | 6 (16) | 1 (17) | 5 (16) | ||
| Decortication | 1 (12) | 1 (3) | 0 (0) | 1 (3) | ||
| Pleurodesis | 1 (12) | 7 (18) | 3 (50) | 4 (13) | ||
| Chest radiotherapy, n (%) | 0.4 | 1.0 | ||||
| Definitive | 2 (25) | 9 (24) | 1 (17) | 8 (26) | ||
| Palliative | 3 (38) | 7 (18) | 2 (33) | 5 (16) | ||
| Platinum/pemetrexed+/-antiangiogenic agents (as a 1st-line treatment for advanced-stage disease), n (%) | 8 (100) | 20 (54) | 4 (67) | 16 (52) | 0.02 | 0.2 |
| ICPi, n (%) | 3 (38) | 13 (35) | 4 (67) | 9 (29) | 1.0 | 0.6 |
| PARPi, n (%) | 4 (50) | 0 (0) | 0 (0) | 0 (0) | 0.0005 | 0.0005 |
AJCC, American Joint Committee on Cancer; CALGB, Cancer and Leukemia Group B; BAP1, BRCA1 associated protein-1; ECOG PS, Eastern Cooperative Oncology Group performance status score; EORTC, European Organization for Research and Treatment of Cancer; EPP, extra-pleural pneumonectomy; ICPi, immune check-point inhibitors; MMR, mismatch repair; MSI, microsatellite instability; mut/Mb, mutations per megabase; NA, not available/not applicable; PARPi, poly (ADP-ribose) polymerase inhibitors; PD-L1, programmeddeath ligand 1; TMB, tumor mutational burden; TPS, tumor proportion score.*n-8; **n-6; ¥n-5; ¥¥n-4.